drugset

drugset / Trial / NCT00140894

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

NCT00140894 ↗

Phase 4 Terminated 62 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

Timeline

Start: 2002-08-06
Primary completion: —
Completion: 2004-10-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rofecoxib	Small molecule	—	—

Indications